Most people have never heard of glycogen as a liver health problem. Fat — specifically NAFLD¹¹ NAFLD
Non-alcoholic fatty liver disease: excess fat accumulation in liver cells unrelated to alcohol consumption, affecting roughly 25% of the global population — gets all the attention. But for carriers of the rs4240624 G allele, the issue begins one step earlier in liver metabolism: the regulation of glycogen²² glycogen
The body's main short-term glucose storage molecule. The liver stores glycogen and releases glucose into the blood between meals to maintain stable blood sugar levels synthesis.

PPP1R3B encodes a regulatory subunit of protein phosphatase 1 (PP1), a master switch that controls glycogen metabolism in the liver. The G allele at rs4240624 — carried by roughly 10% of Europeans and 19% of people of African descent — influences how much glycogen the liver stores, pushing the balance toward accumulation. The downstream effects extend beyond glycogen: elevated liver enzymes, increased NAFLD susceptibility, and a meaningful increase in gallstone risk have all been documented across large population studies.

The Mechanism

Protein phosphatase 1³³ Protein phosphatase 1
PP1: one of the most abundant phosphatases in the body, involved in glycogen metabolism, muscle contraction, protein synthesis, and many other processes. Its activity is tightly regulated by dozens of binding proteins (PP1) is a central regulator of glycogen metabolism. PPP1R3B acts as a glycogen-targeting subunit that directs PP1 to two key enzymes: glycogen synthase (which builds glycogen) and glycogen phosphorylase (which breaks it down). By activating glycogen synthase and inhibiting glycogen phosphorylase, PPP1R3B tips the liver toward glycogen storage.

The rs4240624 G allele is a near-gene regulatory variant that increases PPP1R3B activity or expression. Mouse studies confirm the mechanism directly: overexpression of PPP1R3B causes hepatic glycogen accumulation and elevated plasma ALT, while knockouts produce glycogen-deficient livers. In humans, the minor G allele is associated with increased hepatic X-ray attenuation — a hallmark of glycogen loading — and elevated liver enzymes across multiple large cohorts (n=112,428 in the definitive Stender 2018 study).

Importantly, the excess glycogen from this variant does not appear to directly increase hepatic triglyceride content. This distinguishes rs4240624 from the well-known PNPLA3 rs738409 variant, which directly promotes liver fat accumulation. Instead, the PPP1R3B effect reflects hepatic glycogenosis⁴⁴ hepatic glycogenosis
Abnormal glycogen accumulation in the liver. Can cause hepatomegaly and elevated liver enzymes, and is associated with metabolic syndrome even in the absence of excess fat, a condition that is independently harmful even without steatosis.

The bile and gallstone connection is mechanistically distinct: altered hepatic glycogen-lipid flux changes the composition of bile produced by the liver, with G-allele carriers showing higher concentrations of lithogenic (stone-forming) bile lipid classes. A 2024 validation in the UK Biobank confirmed elevated gallstone disease rates in G carriers with obesity.

The Evidence

The foundational work comes from Stender et al. 2018⁵⁵ Stender et al. 2018
Stender S, Smagris E, et al. "Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride." Hepatology, 2018, which analyzed 112,428 participants across three large cohorts. The minor allele showed consistent ALT elevation (P = 3×10⁻⁴ in the Copenhagen cohort; P = 0.004 in the Dallas Heart Study), and liver disease odds ratios of 1.13–1.23. Crucially, no association was found with hepatic triglyceride content, pointing specifically at glycogen as the culprit.

Hernaez et al. 2013⁶⁶ Hernaez et al. 2013
Hernaez R, McLean J, et al. "Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis." Clin Gastroenterol Hepatol, 2013 used NHANES III data (n=4,804) and found an OR of 1.28 (P=.03) for ultrasound-defined hepatic steatosis in non-Hispanic white adults — suggesting that glycogen accumulation in the liver may mimic the appearance of steatosis on standard ultrasound, even when triglycerides are not elevated.

The gallstone connection was established by Männistö et al. 2021 and 2024⁷⁷ Männistö et al. 2021 and 2024
Männistö VT, Kaminska D, et al. Hepatol Commun 2021; Gastro Hep Adv 2024, who found that among bariatric surgery patients, the G allele produced dramatically different bile acid profiles (total bile acids 35 vs. 109 mM in G carriers vs. non-carriers) and that 13 of 17 bile lipid classes were elevated in G carriers — a pattern that mirrors bile composition in gallstone patients.

A 2024 Taiwan Biobank study (n=150,709) confirmed rs4240624 among seven SNPs significantly associated with metabolic syndrome, underscoring its relevance across diverse populations with high metabolic disease burden.

Practical Actions

For G allele carriers, the primary risk is a liver that stores too much glycogen, especially in the context of a high-carbohydrate diet and metabolic syndrome. Actionable steps center on reducing hepatic glycogen load, supporting liver health, and monitoring for early signs of liver stress and gallstones.

Dietary strategies should focus on moderating refined carbohydrate intake — the primary driver of hepatic glycogen synthesis. Time-restricted eating and reduced meal frequency allow glycogen to be depleted between meals. Avoiding prolonged high-carbohydrate loads (particularly fructose, which is processed almost entirely by the liver) reduces the burden on hepatic glycogen pathways.

Regular liver enzyme monitoring (ALT/AST) is the most direct way to track whether hepatic glycogenosis is causing organ stress. Elevated ALT in the absence of significant hepatic fat on ultrasound should prompt consideration of this genetic mechanism.

Given the documented gallstone risk, G carriers who are female, have obesity, or have additional risk factors should discuss gallstone screening with their physician, especially before planned rapid weight loss (which can mobilize bile cholesterol and precipitate stone formation).

Interactions

PPP1R3B rs4240624 does not appear to directly interact with other common liver SNPs at the molecular level, but its effects are expected to be additive with PNPLA3 rs738409 (the most common NAFLD gene variant) and GCKR rs780094 (a glucokinase regulator also associated with hepatic fat and triglycerides). Individuals carrying risk alleles at multiple these loci face compounding liver stress through distinct pathways — glycogen overload (PPP1R3B), lipid dysregulation (PNPLA3), and impaired glucose sensing (GCKR).

CYP2R1 is a cytochrome P450 enzyme in the liver that performs the first hydroxylation step in vitamin D activation. It converts vitamin D3 ¹¹ Cholecalciferol: the form of vitamin D produced in the skin from sunlight or taken as a supplement (cholecalciferol, from sun exposure or supplements) into 25-hydroxyvitamin D (25(OH)D, also called calcidiol) ²² Calcidiol is the circulating storage form with a half-life of about 3 weeks — the standard marker for vitamin D status, which is the form measured in standard blood tests. Without this conversion step, vitamin D3 remains biologically inactive.

The Mechanism

The rs10741657 variant is located in the promoter region of the CYP2R1 gene, affecting how much enzyme is produced ³³ Promoter variants don't change the protein itself — they change how much of the protein the cell makes. The A allele reduces CYP2R1 transcription, resulting in lower enzyme levels in the liver. This means that for a given amount of vitamin D3 intake (from sun or supplements), less is converted to the active 25(OH)D form. Genome-wide association studies (GWAS) have consistently identified this variant as one of the strongest genetic determinants of circulating 25(OH)D levels.

The Evidence

A GWAS meta-analysis involving over 79,000 individuals⁴⁴ A GWAS meta-analysis involving over 79,000 individuals
Jiang X et al. Nature Communications 2018 — GWAS in 79,366 Europeans on the genetic architecture of 25(OH)D levels confirmed that variants near CYP2R1, including rs10741657, significantly affect blood 25(OH)D concentrations. A systematic review and meta-analysis⁵⁵ systematic review and meta-analysis
Duan L et al. Effects of CYP2R1 gene variants on vitamin D levels and status, 2018 found that carriers of risk alleles had an increased risk of vitamin D deficiency (OR 1.09, 95% CI 1.03-1.15). Carriers of the A allele have lower baseline 25(OH)D levels and may require higher vitamin D3 doses to achieve the same blood levels as non-carriers.

The Double Hit with VDR

If you carry both a CYP2R1 activation variant (less D3 converted to 25(OH)D) and a VDR receptor variant (cells respond less to circulating vitamin D), you face a compounded challenge. You produce less active vitamin D AND your cells are less responsive to what you do produce. This makes vitamin D optimization through testing and supplementation particularly important.

Practical Implications

If you carry the A allele, you likely need higher vitamin D3 supplementation doses than the general recommendation to achieve optimal blood levels. The only way to know your ideal dose is to test, supplement, and retest. Many people with this variant find they need 3,000-5,000 IU daily (or more) to maintain optimal levels, especially in winter months or at higher latitudes.

Interactions

CYP2R1 interacts with VDR (rs1544410) — reduced activation combined with reduced receptor sensitivity creates a compounded vitamin D challenge.

The insulin system is not just controlled by receptors and hormones — it is also governed by the levels of the proteins that modulate those receptors. ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is a well-established negative regulator of insulin receptor signaling: it physically binds the receptor's alpha-subunit and blocks the conformational change that activates tyrosine kinase, throttling the downstream cascade before it can begin. Variants in the 3'UTR regulatory region of the ENPP1 gene — including the chromosomal locus associated with rs10954640 — can alter ENPP1 mRNA stability and expression levels, thereby affecting how strongly this brake is applied.

Genomic note: dbSNP places rs10954640 at chr7:139038996 (GRCh38), which maps to an intergenic region between ZC3HAV1L and ZC3HAV1 on chromosome 7 — distinct from the chr6q23.2 location of the ENPP1 gene itself. The variant carries no ClinVar annotation and has no directly published functional or association studies at time of research. Its classification as an "ENPP1 3'UTR variant" in this platform entry reflects its identification in ENPP1 haplotype studies and as a candidate expression-QTL, but independent functional confirmation is pending. Evidence level is accordingly rated emerging.

The Mechanism

ENPP1 expression is tightly regulated at the mRNA level, and the 3'UTR plays a key role in this control. The 3'UTR of ENPP1 contains binding sites for microRNAs and RNA-binding proteins that influence transcript stability and translation efficiency. A variant in this region can shift ENPP1 protein output up or down, which in turn shifts the degree of insulin receptor inhibition the protein imposes.

Higher ENPP1 expression means more inhibition of insulin receptor autophosphorylation — blunting the subsequent activation of IRS-1, PI3K, and Akt, and reducing GLUT4 translocation to the cell surface in muscle and adipose tissue. The T allele at rs10954640 is associated with the regulatory context that may favor higher ENPP1 expression levels in relevant metabolic tissues, though direct eQTL confirmation has not been published for this specific position.

The established biology of ENPP1 overexpression in the liver¹¹ ENPP1 overexpression in the liver
Dong et al. Diabetes 2005 demonstrates that even modest increases in hepatic ENPP1 protein levels (2–3 fold) are sufficient to impair insulin receptor tyrosine kinase activation, elevate gluconeogenic enzyme expression, and raise fasting glucose by 30–40 mg/dl in animal models. This mechanistic framework establishes why regulatory variants that alter ENPP1 expression are biologically plausible determinants of insulin sensitivity.

The Evidence

Direct association data for rs10954640 specifically are not available in the published literature as of 2026. The framework for this entry derives from the extensive mechanistic and epidemiological evidence for the ENPP1 locus generally:

The K121Q coding variant (rs1044498)²² K121Q coding variant (rs1044498)
Goldfine et al. Endocr Rev 2008 increases ENPP1–insulin receptor binding affinity 2–3 fold and represents the most studied ENPP1 variant. 3'UTR variants in the same gene were included in the haplotype analysis of Meyre et al., who reported that an ENPP1 risk haplotype — encompassing both the K121Q coding change and 3'UTR alleles — was associated with childhood obesity and glucose intolerance across European cohorts³³ associated with childhood obesity and glucose intolerance across European cohorts
Meyre et al. Nat Genet 2005. The 3'UTR component of this haplotype contributes independently to expression variation, and rs7754561 (c.*1043A>G in the ENPP1 3'UTR on chr6) has been identified in ClinVar as a risk factor for obesity.

Because the variant's effect on insulin signaling is likely to be smaller in magnitude than the K121Q coding change — reflecting regulatory rather than direct protein-function alteration — the clinical implications are more modest. Users carrying TT or CT genotypes at this locus should understand the evidence is preliminary and that the K121Q result (rs1044498) is the better-validated primary ENPP1 risk marker.

Practical Actions

ENPP1-mediated insulin resistance responds well to interventions that improve insulin sensitivity through insulin-receptor-independent pathways. Skeletal muscle contraction triggers GLUT4 translocation directly, bypassing the ENPP1 block. Reducing postprandial glucose spikes lowers the burden on a partially impaired insulin signaling cascade. Monitoring fasting insulin (not just glucose) gives the earliest signal of impaired insulin action.

Interactions

This variant sits in the same gene as ENPP1 K121Q (rs1044498). The K121Q coding variant is the better-characterized risk allele and should be checked alongside this regulatory variant — the two may operate additively within the same haplotype. Downstream of ENPP1, IRS-1 (rs2943641) is the primary insulin receptor substrate phosphorylation target; reduced ENPP1 throughput from elevated expression compounds with impaired IRS-1 signaling. TCF7L2 (rs7903146) governs beta-cell incretin response; combined impairment at the receptor level (ENPP1) and the secretory level (TCF7L2) represents a double burden on glucose homeostasis.

ABCA7 (ATP-binding cassette sub-family A member 7) is a membrane-spanning lipid transporter expressed at its highest levels in neurons and microglia — exactly the cells responsible for managing amyloid-beta (Aβ) accumulation in the aging brain. The protein ferries phospholipids and cholesterol across cell membranes, a function that turns out to be central to Aβ clearance, lipid raft organisation, and amyloid precursor protein (APP) processing. Loss-of-function variants in ABCA7 consistently rank as the strongest non-APOE genetic risk factors for late-onset Alzheimer's disease (LOAD) in people of European ancestry, and carry even larger effect sizes in African American cohorts.

rs113809142 is the c.4416+2T>G variant, a single nucleotide change at the splice donor site of intron 32 in ABCA7 (also annotated as IVS32+2T>G). This position — immediately adjacent to the GU dinucleotide that marks the boundary between exon and intron — is a canonical splice signal. The G allele disrupts the splice donor consensus sequence, causing intron retention or exon skipping and generating a premature termination codon. RNAseq data from carriers confirm that the mutant allele extends into intronic sequence rather than splicing correctly.

The Mechanism

When ABCA7 is haploinsufficient, neurons and microglia operate with roughly half the normal transporter capacity. Three downstream consequences compound in the direction of Aβ accumulation:

1. Impaired microglial phagocytosis. Fu et al. 2016¹¹ Fu et al. 2016
   ABCA7-null mice showed substantially reduced clearance of Aβ oligomers by microglia and macrophages; ABCA7 transcription was simultaneously up-regulated in AD brains, suggesting attempted compensation. Without adequate ABCA7, the phosphatidylserine flip that signals apoptotic cells and protein aggregates for phagocytosis is impaired, and phagosomes form less efficiently.

2. SREBP2-BACE1 pathway activation. ABCA7 deficiency elevates SREBP2 (sterol regulatory element-binding protein 2), which up-regulates BACE1 — the β-secretase enzyme that cleaves APP into Aβ. Simultaneously, altered phospholipid composition of lipid rafts may increase the probability of BACE1 encountering APP in the membrane, further accelerating Aβ production.

3. Mitochondrial lipid dysregulation. Kawatani et al. 2023²² Kawatani et al. 2023
   iPSC-derived neuron and organoid models; electron microscopy confirmed enlarged dysmorphic mitochondria; phosphatidylglycerol and cardiolipin levels specifically reduced in ABCA7-deficient cells demonstrated that ABCA7 loss disrupts transport of phosphatidic acid from the endoplasmic reticulum to mitochondria, depleting the cardiolipin precursors that mitochondria require for normal respiration. Reduced ATP production and increased oxidative stress follow.

More recently, von Maydell et al. 2025³³ von Maydell et al. 2025
iPSC-derived neurons; ABCA7 LOF variants from the ROSMAP cohort; transcriptomics and lipidomics identified elevated saturated phosphatidylcholine as a key metabolic signature of ABCA7 dysfunction, with downstream mitochondrial uncoupling and neuronal hyperexcitability. Critically, this phenotype was fully rescued by CDP-choline supplementation in neurons, pointing to a potentially targetable metabolic bottleneck.

The Evidence

The c.4416+2T>G variant was among the splice-site LOF alleles discovered in the landmark Steinberg et al. 2015 Nature Genetics study⁴⁴ Steinberg et al. 2015 Nature Genetics study
whole-genome sequencing of ~2,636 Icelanders; 3,419 cases and >151,000 controls; individual LOF variants aggregated to OR 2.12 in Icelanders, OR 2.03 combined across European and US cohorts. This established ABCA7 LOF haploinsufficiency as a LOAD risk mechanism of genome-wide significance.

In a European American replication cohort, Del-Aguila et al. 2015⁵⁵ Del-Aguila et al. 2015
3,476 European Americans; gene-level burden test found the c.4416+2T>G MAF was 0.002 in cases versus 0.0012 in controls, with the aggregate LOF variant burden significant at P=0.039 (OR 1.54). Individual variant power was limited by the rarity of c.4416+2T>G in non-Icelandic populations; the combined Icelandic OR of 4.42 for this specific variant likely reflects founder-effect enrichment.

Allen et al. 2017 Neurology: Genetics⁶⁶ Allen et al. 2017 Neurology: Genetics
Mayo Clinic ROSMAP cohort; six ABCA7 LOF variants including rs113809142; brain expression analysis; autopsy-confirmed diagnoses reported OR 2.97 for LOAD and OR 3.05 for non-AD neuropathologies, underscoring that ABCA7 haploinsufficiency raises risk broadly across late-life neurodegenerative pathology — not exclusively Alzheimer's.

Campbell et al. 2022⁷⁷ Campbell et al. 2022
clinical deep phenotyping of 67 ABCA7 LOF carriers; mean age at onset 75.6 years; 76% amnestic presentation; 10/11 autopsy cases confirmed Alzheimer neuropathology confirmed a predominantly late-onset amnestic syndrome in ABCA7 LOF carriers, phenotypically similar to sporadic LOAD but with somewhat younger onset and higher family history burden.

Practical Actions

No current therapy reverses haploinsufficiency in a living carrier. The actionable levers are those that support the biological processes ABCA7 normally facilitates: phospholipid metabolism, amyloid-β clearance capacity, and mitochondrial function. CDP-choline (citicoline) normalises the phosphatidylcholine deficit in ABCA7-deficient neurons in vitro and is safe for long-term use; while definitive human trials in ABCA7 carriers are still pending, the mechanistic evidence and its established safety profile make it the highest-priority supplement recommendation here. NMN or NR (NAD+ precursors) similarly rescued mitochondrial function in cell models.

Proactive cognitive monitoring — baseline neuropsychological testing in mid-life, annual self-monitoring, and follow-up if any cognitive concerns arise — is warranted for carriers given the substantial increase in LOAD risk. Earlier detection of cognitive decline enables timely access to emerging disease-modifying therapies (e.g., anti-amyloid antibodies) that are most effective before extensive Alzheimer pathology accumulates.

Interactions

ABCA7 haploinsufficiency interacts with APOE genotype: APOE ε4 carriers with concurrent ABCA7 LOF variants face compounding impairments across both the lipid transport (ABCA7) and lipid clearance/APOE-receptor axis, with observational data suggesting substantially earlier age at onset when both risk alleles are present. The ABCA7–APOE interaction has not yet been characterised for this specific splice variant but is biologically plausible given shared lipid-transport pathway involvement.

ABCA7 LOF variants have also been reported at modestly elevated frequency in Parkinson's disease with dementia (OR ~4.94 for the LOF variant aggregate in one cohort; PMID 27066581), consistent with the Allen et al. finding of elevated risk for Lewy body pathology.

Inside every naive T cell, the T-bet transcription factor¹¹ T-bet transcription factor
encoded by TBX21 (T-box transcription factor 21); the master regulator of Th1 cell differentiation; activates interferon-gamma and physically represses the Th2 regulators GATA3 and IL-4 sets the immune system's allergic thermostat. When T-bet activity is high, CD4+ T cells commit to the Th1 path — mounting antiviral and antibacterial responses that suppress IgE production and eosinophil activation. When T-bet is constrained, the Th2 program fills the vacuum, priming the immune system for IgE-mediated allergic inflammation. rs11650354 is an intronic variant within TBX21 that, together with the neighboring downstream variant rs16947078, defines a risk haplotype strongly associated with allergic asthma in European-ancestry children. Carriers of the T allele — and especially TT homozygotes — appear to carry reduced Th1 tone at this locus, tilting the immune system toward the Th2 phenotype underpinning allergic airway disease.

The Mechanism

rs11650354 lies within an intron of TBX21. It does not alter the T-bet protein sequence — there is no amino acid change or splice disruption. Its functional significance is regulatory: the T allele is thought to influence how TBX21 is expressed in T-lymphocyte subsets, reducing the quantity of T-bet available to enforce Th1 polarization. The exact intronic regulatory element has not been functionally characterized in isolation, but the variant overlaps with [open chromatin regions accessible in T cells | eQTL data in the TBX21-TBKBP1 locus identify rs11650354 as lying within chromatin accessible to transcription factor binding in lymphocyte cell lines], suggesting it resides within an active regulatory element influencing transcriptional output. When T-bet output is reduced, the transcriptional repression of GATA3 and other Th2-promoting regulators weakens, allowing the Th2 program to predominate. The downstream consequences are increased IgE class-switching, mast cell and eosinophil priming, and heightened airway reactivity — the hallmarks of allergic asthma. The systemic sclerosis data²² systemic sclerosis data
Kariuki et al. 2010 showed TT carriers have elevated serum IL-4, IL-5, and IL-13 levels compared to CC homozygotes, directly demonstrating the Th2 cytokine excess associated with TT genotype provides functional support: TT homozygotes show measurably elevated Th2 cytokines (IL-4, IL-5, IL-13) versus CC carriers, consistent with reduced T-bet suppression of the Th2 effector program.

The Evidence

The primary evidence for allergic asthma association comes from the 2008 Munthe-Kaas et al. study³³ 2008 Munthe-Kaas et al. study
948 children from the Environment and Childhood Asthma (ECA) cohort, Norway; 12 TBX21-region SNPs genotyped; outcomes assessed at age 10 including allergic asthma, non-allergic asthma, spirometry, methacholine challenge, FeNO, and IgE. Two SNPs — rs11650354 and rs16947078 — showed significant independent associations with allergic asthma, and the risk haplotype containing both variants carried a striking [odds ratio of 8.3 (95% CI 2.5–26.9) | The wide confidence interval reflects the rarity of homozygous risk haplotype carriers in the study cohort; the point estimate is large but should be interpreted with appropriate caution pending larger replication studies in independent European cohorts] for allergic asthma in homozygous carriers. Critically, the association was specific to allergic asthma — not to non-allergic asthma or allergy alone — consistent with a mechanism acting on the IgE-mediated arm of the Th2 response.

Functional evidence linking the T allele to Th2 cytokine excess comes from the Kariuki et al. 2010 systemic sclerosis study⁴⁴ Kariuki et al. 2010 systemic sclerosis study
902 SSc patients, 4,745 controls; North American white population; TT genotype OR 3.37, P=1.4×10⁻¹⁵; functional cytokine profiling showed TT carriers elevated in IL-4, IL-5, IL-13. TT homozygotes showed elevated serum Th2 cytokines, directly confirming the predicted biological consequence of reduced T-bet activity at this locus. A 2009 German study⁵⁵ 2009 German study
Suttner et al.; 43 TBX21 polymorphisms in German children; three tagging SNPs increased childhood asthma risk with ORs 1.39–2.60; TBX21 combined with HLX1 variants gave >3-fold increased asthma risk in a gene-risk-score model confirmed that TBX21 variants, likely including the rs11650354 haplotype block, increase childhood asthma risk, and that TBX21 interacts with HLX1 (another T-cell transcription factor gene) to amplify asthma risk beyond either gene alone.

The association is predominantly observed in European-ancestry populations, where the T allele frequency is approximately 18%. It is substantially rarer in East Asian populations (~3.5%), which may explain why studies in Korean and other Asian cohorts have not replicated this signal — the low T allele frequency makes power to detect TT homozygote effects very limited in these cohorts.

Practical Actions

For CT heterozygotes, the T allele adds marginal directional risk within the haplotype context; early symptom awareness and targeted allergen management are the primary practical implications. TT homozygotes, though rare (~2.7% globally, ~3% in Europeans), carry a genuinely elevated allergic asthma risk from both alleles and warrant proactive respiratory evaluation.

The reduced T-bet tone that the T allele appears to confer means the Th1 brake on Th2 responses is less effective — the same allergen load elicits a stronger IgE and eosinophil response than in CC individuals. Reducing indoor allergen exposure directly addresses this vulnerability. Early spirometry and IgE assessment establish objective baselines before airway remodeling occurs, supporting earlier intervention if asthma develops.

Interactions

rs11650354 and rs16947078 together constitute the TBX21 risk haplotype identified in the Munthe-Kaas 2008 study. Carriers of the T allele at rs11650354 are at meaningfully higher risk if they also carry the G allele at rs16947078 — the two variants act in the same haplotype block and their co-inheritance is what defines the OR 8.3 effect seen for haplotype homozygosity. A third TBX21 variant, rs4794067 (upstream regulatory, associated with aspirin-induced asthma and nasal polyps), operates through a distinct regulatory entry point at the 5-prime end of TBX21 and compounds T-bet deficiency when co-inherited with the rs11650354 / rs16947078 haplotype. The TBX21 + HLX1 interaction identified by Suttner et al. suggests that TBX21 risk alleles also interact with variants in other Th1/Th2 transcription factor genes beyond the TBX21 locus itself.

Deep within an intron of the PPARG¹¹ Peroxisome Proliferator-Activated Receptor Gamma — the master transcription factor controlling adipocyte differentiation, lipid storage, and insulin sensitization gene sits a variant that quietly influences how well your body responds to caloric restriction and how efficiently it maintains circulating vitamin D levels. rs1175540 is not the famous Pro12Ala variant (rs1801282) — it does not change the PPARG protein sequence — but by altering an intronic regulatory element, it modulates how much PPARG activity your adipose tissue generates, with downstream effects on fat mobilization, glucose metabolism, and vitamin D homeostasis.

The Mechanism

rs1175540 sits in intron 2 of the PPARG gene (chromosome 3, GRCh38 position 12,423,744). Intronic variants in PPARG can act as cis-regulatory elements²² cis-regulatory elements
Cis-regulatory elements are DNA sequences within or near a gene that control its transcription level, typically by serving as binding sites for transcription factors or influencing chromatin accessibility. The PPARG locus contains multiple such regulatory elements — as demonstrated by Lee et al.³³ Lee et al.
Lee et al. Allele-specific quantitative proteomics unravels molecular mechanisms modulated by cis-regulatory PPARG locus variation. Nucleic Acids Res, 2017, who showed that cis-regulatory SNPs at the PPARG locus alter transcription factor binding and PPARG expression levels, directly affecting insulin sensitivity in adipose tissue. The rs1175540 A allele is in linkage disequilibrium⁴⁴ LD: inherited together more often than chance — variants in LD tend to track each other across populations with nearby variants including rs1175544, and the haplotype block it tags appears to influence PPARG transcriptional output, though the precise causal element has not been isolated.

PPARG governs the decision of precursor cells to become fat cells. Altered PPARG expression affects both the rate of adipogenesis⁵⁵ adipogenesis
Adipogenesis: the differentiation of precursor cells into mature adipocytes (fat cells) and the metabolic flexibility of existing adipose tissue. Vitamin D signaling intersects with PPARG at multiple levels: PPARG activates vitamin D receptor expression in adipocytes, and adipose tissue sequesters fat-soluble vitamin D — so variants that shift adipose PPARG activity can indirectly influence circulating 25(OH)D concentrations.

The Evidence

Matsuo et al.⁶⁶ Matsuo et al.
Matsuo T et al. PPARG genotype accounts for part of individual variation in body weight reduction in response to calorie restriction. Obesity (Silver Spring), 2009 placed 95 middle-aged Japanese women (BMI ≥25 kg/m²) on a structured 14-week, 1,200 kcal/day caloric restriction program. Body weight fell by 7.7±3.1 kg (−11.3±4.4%) overall, but the response varied substantially by PPARG genotype. rs1175540 was one of six PPARG SNPs significantly associated with the magnitude of weight reduction — the haplotype block containing rs1175540 and rs1175544 (the strongest individual signal at P=0.004) accounted for ~7% of variance in weight loss response. This means that for a given caloric deficit, the PPARG haplotype predicted how much weight a person actually lost, above and beyond dietary adherence alone.

Sadarangani et al.⁷⁷ Sadarangani et al.
Sadarangani SP et al. Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons. Hum Vaccin Immunother, 2016 examined 159 adults aged 50–74 and found that rs1175540 was significantly associated with baseline 25-(OH)D levels (p=0.02), along with two neighboring PPARG SNPs (rs1151996 and rs1175544). Because vitamin D is fat-soluble and stored in adipose tissue, PPARG variants that modulate adipose biology predictably alter circulating vitamin D availability — even when dietary intake is similar.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — appear to have a PPARG regulatory profile that responds less efficiently to caloric restriction and maintains lower circulating 25(OH)D. These individuals may need to work harder in terms of dietary precision during weight-loss phases and should pay attention to vitamin D status year-round, since their adipose tissue sequesters vitamin D more effectively (or maintains it less efficiently depending on seasonal patterns). Monitoring serum 25(OH)D and adjusting vitamin D3 supplementation accordingly provides a concrete, genotype-informed lever for managing this risk.

Interactions

rs1175540 is in LD with rs1175544, which showed the strongest individual weight-loss signal in the Matsuo 2009 study — these two SNPs likely tag the same functional haplotype. The PPARG Pro12Ala variant (rs1801282) independently affects insulin sensitivity through a protein-coding mechanism; the combined effect of rs1801282 and the rs1175540/rs1175544 regulatory block on adipose PPARG activity has not been directly studied but represents a plausible interaction worth considering when reviewing PPARG results holistically.

Within the IFNL4 gene on chromosome 19, the major functional switch for hepatitis C risk is the rs368234815 ΔG frameshift polymorphism¹¹ rs368234815 ΔG frameshift polymorphism
the causal variant that controls whether functional IFN-λ4 protein is produced at all. But not all ΔG carriers face the same risk. A second coding variant in exon 2 — rs117648444, which swaps a proline for a serine at position 70 of the IFN-λ4 protein (p.Pro70Ser) — significantly modulates how active the resulting protein actually is. The Ser70 form (S70) is substantially weaker than the ancestral Pro70 (P70), and ΔG carriers who produce the attenuated S70 protein achieve better hepatitis C clearance outcomes than those producing the fully active P70 form. This creates a functional three-tier hierarchy for IFNL4: TT/TT (no protein) > ΔG-S70 (weak protein) > ΔG-P70 (fully active protein).

The Mechanism

rs117648444 is a missense variant²² missense variant
a coding SNP that changes a single amino acid in the protein sequence. On the IFNL4 minus strand, the coding change is c.208C>T; on the genomic plus strand (as reported in genome files), the alleles are G (reference, Pro70) and A (alternate, Ser70). The substitution of serine for proline at position 70 disrupts the local secondary structure of the IFN-λ4 protein — proline is a rigid, helix-breaking residue, while serine introduces a hydroxyl group and greater flexibility. The result is an IFN-λ4 protein with substantially lower capacity to activate downstream interferon-stimulated genes³³ interferon-stimulated genes
ISGs; hundreds of genes whose protein products directly inhibit viral replication, and reduced antiviral activity against viral challenge models.

Crucially, the A allele (Ser70) is only found on haplotypes that also carry the rs368234815 ΔG allele — it has never been observed on the TT (null) background. This means the rs117648444 variant is uninformative for TT/TT individuals (who produce no IFN-λ4 regardless), and its clinical significance is entirely confined to ΔG carriers. The three haplotypes observed in humans are: (1) IFNL4-TT with rs117648444-G (no protein); (2) IFNL4-ΔG with rs117648444-G (fully active P70 protein); and (3) IFNL4-ΔG with rs117648444-A (attenuated S70 protein).

The Evidence

The variant was characterised in Galmozzi & Aghemo 2014⁴⁴ Galmozzi & Aghemo 2014
"Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients", showing that ΔG carriers with the S70 modifier had significantly greater early viral RNA decline than ΔG-P70 carriers, approaching the response of TT/TT non-producers.

The mechanistic evidence was established by Terczynska-Dyla et al. 2014⁵⁵ Terczynska-Dyla et al. 2014
"Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes" using recombinant protein assays: the S70 protein induced significantly lower intrahepatic ISG expression and had weaker antiviral activity than the P70 protein in direct comparison. The same study confirmed that, in population cohorts, individuals predicted to produce only the S70 form had better spontaneous HCV clearance rates than P70 producers — intermediate between TT/TT (best) and ΔG-P70 (worst).

A 2015 comparative analysis of IFNL4 and IFNL3 functional variants⁶⁶ comparative analysis of IFNL4 and IFNL3 functional variants
Terczynska-Dyla et al., Journal of Hepatology found that rs117648444 adds independent prognostic information beyond rs368234815 alone. In African American participants — where the ΔG allele is common and LD structure differs substantially from Europeans — rs368234815 combined with rs117648444 provided stronger association with HCV outcomes than either variant alone or than the traditional rs12979860 IL28B marker.

The clinical reach extends beyond HCV. In IFN-treated HBeAg-negative chronic hepatitis B patients⁷⁷ IFN-treated HBeAg-negative chronic hepatitis B patients
Galmozzi et al. 2018, Liver International, the combination of rs368234815 and rs117648444 genotypes strongly predicted HBsAg seroclearance at 15 years: the 15-year cumulative probability of HBsAg loss was comparable between S70 carriers and TT/TT individuals (both significantly higher than P70 producers), suggesting the same IFN-λ4 activity gradient that governs HCV outcomes also applies to hepatitis B treatment.

A 2017 study of HCV genotype 3 patients in India⁸⁸ HCV genotype 3 patients in India
Datta et al., PMID 28727946 found that failure to genotype rs117648444 causes confounding in IFNL locus association studies: tag SNPs in linkage disequilibrium with ΔG that happen to be correlated with the S70 modifier will show misleadingly strong or weak associations with treatment response depending on their LD pattern.

Practical Implications

For clinical purposes, rs117648444 is most useful as a refinement tool for ΔG carriers identified by rs368234815 genotyping. A ΔG carrier who also has the S70 modifier (rs117648444-AG or AA) faces a different prognosis than a P70 ΔG carrier (GG at this locus with ΔG at rs368234815): their treatment response profile is closer to that of TT/TT non-producers than to the worst ΔG-P70 subgroup.

For the majority of individuals who are TT/TT at rs368234815, this variant carries no clinical significance: they produce no functional IFN-λ4 regardless of what they carry at rs117648444. For individuals who have not been exposed to hepatitis C and have no ongoing risk, the variant is informationally interesting but does not require clinical action.

Interactions

rs117648444 is functionally downstream of rs368234815. The ΔG allele at rs368234815 is the prerequisite for any effect at rs117648444 — only ΔG/TT or ΔG/ΔG individuals at rs368234815 can benefit from S70 status. Among those ΔG carriers, rs117648444 sub-stratifies by protein activity: the A allele (S70) attenuates IFN-λ4 function and shifts outcomes toward the TT/TT tier. For compound genotype interpretation across both variants, see the interaction analysis in the rs368234815 entry. rs12979860 (the original "IL28B" C/T marker) is a proxy tag for the ΔG/TT distinction and does not capture the P70S modification — making combined genotyping of rs368234815 and rs117648444 the most informative approach.

Apolipoprotein B (apoB) is the indispensable structural protein of atherogenic lipoproteins — LDL, VLDL, and IDL. Every LDL particle contains exactly one molecule of apoB-100, a 4,536-amino-acid protein that serves both as the scaffolding for lipoprotein assembly in the liver and as the docking ligand for LDL receptor recognition. When rs121918389 introduces a premature stop codon at position 1477 (Q1477X), the result is apoB-32 — a truncated protein containing only the first 1,476 amino acids of apoB-100, representing just 32% of the full-length protein. This truncation defines one of the founding mutations of familial hypobetalipoproteinemia (FHBL)¹¹ familial hypobetalipoproteinemia (FHBL)
FHBL is a disorder of very low LDL and apoB levels caused by APOB loss-of-function mutations; OMIM 615558.

The Mechanism

The p.Gln1477Ter stop-gain eliminates the C-terminal two-thirds of apoB-100, including the LDL receptor-binding domain (located between residues ~3000–3500). McCormick et al.²² McCormick et al.
McCormick et al. Apolipoprotein B-32: a new truncated mutant of human apolipoprotein B capable of forming particles in the low density lipoprotein range. Biochim Biophys Acta, 1992 showed that apoB-32 is remarkably unusual among short apoB truncations: it is the shortest known apoB variant capable of forming particles in the LDL density range. However, the majority of apoB-32 partitioned to the HDL and lipoprotein-depleted (d>1.21 g/mL) fractions, with only trace amounts appearing in LDL and none detected in VLDL. This means the liver cannot assemble and secrete apoB-32 as functional VLDL particles, causing hepatic fat accumulation while simultaneously depriving the circulation of its normal complement of LDL cholesterol.

In heterozygotes, one APOB allele produces full-length apoB-100 and the other produces apoB-32. The result is approximately 50% reduction in circulating LDL-C and apoB concentrations compared to unaffected individuals. Because apoB-32 is shorter than apoB-48 (the intestinal isoform that terminates at residue 2152), the intestinal chylomicron pathway is preserved through the wild-type allele — heterozygotes retain fat absorption capacity, which is why severe nutritional deficiency is uncommon in this group.

The Evidence

GeneReviews on APOB-FHBL³³ GeneReviews on APOB-FHBL
Burnett, Hooper, Hegele. APOB-Related Familial Hypobetalipoproteinemia. GeneReviews, 2021 summarizes the clinical spectrum: heterozygotes have plasma LDL-C typically below the 5th percentile for age and sex (~3.0 mmol/L or 115 mg/dL), with LDL-C and apoB concentrations approximately one-third of normal. Heterozygotes are usually asymptomatic, though hepatic steatosis — with a three- to five-fold increase in hepatic fat content versus population norms — is common. About 5–10% of heterozygous carriers develop nonalcoholic steatohepatitis (NASH) that may require medical attention; cirrhosis is rare.

Paradoxically, heterozygous APOB-FHBL confers protection against atherosclerotic cardiovascular disease due to lifelong reductions in LDL cholesterol. This mirrors the cardiovascular protection observed with PCSK9 loss-of-function variants and statin therapy — reinforcing that lower LDL, even when caused by a truncating variant, is cardioprotective.

Tarugi et al. 2001⁴⁴ Tarugi et al. 2001
Tarugi et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. Journal of Lipid Research, 2001 examined apoB truncation length and hepatic outcomes across three kindreds, finding that fatty liver develops invariably in carriers of short and medium truncations (shorter than apoB-48), while longer forms require additional environmental co-factors such as alcohol or metabolic syndrome. The Q1477X mutation producing apoB-32 falls squarely in the "short truncation" category and reliably causes hepatic steatosis.

Practical Actions

For heterozygous carriers (AG genotype), the primary clinical priorities are: (1) confirming the lipid phenotype, (2) monitoring for hepatic steatosis progression, and (3) maintaining fat-soluble vitamin sufficiency. Although heterozygotes rarely develop severe vitamin deficiency, the three- to five-fold increase in hepatic fat indicates that fat absorption and transport are measurably impaired. Monitoring fat-soluble vitamin levels (particularly vitamins E and D) annually is warranted.

Dietary fat intake does not need to be severely restricted in heterozygotes — unlike biallelic FHBL, where a low-fat diet is essential. However, minimizing hepatic fat accumulation by reducing refined carbohydrates and excess dietary fat is reasonable. Alcohol should be minimized, as it is an established hepatic steatosis co-factor.

Interactions

The Q1477X allele interacts in compound heterozygous fashion with other APOB truncating or loss-of-function variants. Compound heterozygosity or homozygosity for APOB truncations produces biallelic FHBL, which resembles abetalipoproteinemia with severe fat malabsorption, fat-soluble vitamin deficiency, and neurological complications if untreated. This is an autosomal recessive severe form requiring aggressive fat-soluble vitamin supplementation and low-fat diet.

The APOB R3527Q variant (rs5742904), which causes familial hypercholesterolemia through defective LDL receptor binding rather than truncation, represents the opposite end of the APOB clinical spectrum — same gene, mechanistically opposite phenotype. Clinicians evaluating unexplained hypocholesterolemia should consider this locus, just as they consider rs5742904 for familial hypercholesterolemia.

Inside the hypothalamus, a cluster of roughly 20,000 neurons called the suprachiasmatic nucleus (SCN)¹¹ suprachiasmatic nucleus (SCN)
The brain's master circadian clock, located in the hypothalamus above the optic chiasm; it generates and coordinates ~24-hour biological rhythms throughout the body fires in near-perfect 24-hour cycles, orchestrating sleep timing, hormone release, and metabolism. Keeping those neurons synchronized — not just cycling individually but entraining as a coherent population — requires molecular conductors. One of the most important is RGS16²² RGS16
Regulator of G-protein Signaling 16; accelerates inactivation of Gαi/o subunits, terminating cAMP signaling pulses and creating a rhythmic window for intercellular synchrony in the SCN.

The variant rs12736689 sits approximately 20 kilobases downstream of the RGS16 gene, in a regulatory region that influences how much RGS16 protein the SCN produces. The C allele — rare at roughly 4% globally — is associated with the strongest morningness signal ever detected in human genetics. Out of hundreds of thousands of genetic variants tested in three independent studies totalling nearly a million people, this single locus has emerged at the top of the chronotype ranking every time.

The Mechanism

RGS16 controls chronotype by gating cAMP³³ cAMP
Cyclic AMP (cyclic adenosine monophosphate), a second messenger that amplifies signals from G-protein-coupled receptors; in the SCN, timed cAMP pulses coordinate neuron-to-neuron communication and synchronize the distributed clock network rhythms within the SCN. RGS16 protein levels themselves cycle over the 24-hour day, creating a timed window during which cAMP can accumulate. This rhythmic cAMP pulse synchronizes the dorsomedial SCN (which drives peripheral body-clock timing) with the ventrolateral SCN (which receives light input from the retina).

Doi et al. (2011)⁴⁴ Doi et al. (2011)
Doi M et al. Circadian regulation of intracellular G-protein signalling mediates intercellular synchrony and rhythmicity in the suprachiasmatic nucleus. Nature Communications, 2011 showed that when RGS16 is deleted in mice, the circadian cAMP rhythm collapses and the behavioral circadian period lengthens. A longer internal period means the clock runs slow relative to the 24-hour day — the animal drifts toward later and later timing, the mouse equivalent of an extreme evening chronotype.

The rs12736689 C allele is in strong linkage disequilibrium⁵⁵ linkage disequilibrium
LD (r²=0.89): the two variants are inherited together so frequently that knowing one allele predicts the other with ~89% accuracy (r²=0.89) with rs1144566, a missense variant (H137R) in the RGS16 coding sequence. The combined evidence suggests that the regulatory and structural variants at this locus jointly modulate RGS16 activity in the SCN, with higher activity corresponding to tighter cAMP gating and a faster, morning-biased clock.

The Evidence

The RGS16 locus is the most robustly replicated single locus in human chronotype genetics, having emerged independently in three large-scale GWAS using different populations and study designs.

Hu et al. (2016)⁶⁶ Hu et al. (2016)
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nature Communications, 2016 identified rs12736689 as the top hit in 89,283 23andMe participants, with the T allele (non-morningness) showing OR 0.74 (95% CI 0.69–0.79) at P=7.0×10⁻¹⁸ — meaning the C allele confers approximately 1.35-fold higher odds of being a morning person per allele. Seven of the 15 significant loci clustered near established circadian genes, and RGS16 stood apart as the most significant of all.

Jones et al. (2016)⁷⁷ Jones et al. (2016)
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 independently identified the same RGS16 locus (lead SNP rs516134, in high LD with rs12736689) as the top chronotype hit in the UK Biobank, with OR 1.21 for the morningness allele at P=3×10⁻¹².

The definitive meta-analytic confirmation came from Jones et al. (2019)⁸⁸ Jones et al. (2019)
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019, expanding the chronotype locus catalog to 351 genome-wide significant loci in 697,828 participants. The RGS16 locus remained the top hit. Mendelian randomization in this study established that the genetic component of morningness causally associates with better mental health outcomes — likely because earlier chronotype aligns more closely with typical daylight-hour social and work schedules.

Practical Implications

For TT homozygotes (the large majority), circadian timing sits at the population average — slightly toward the evening end of the spectrum relative to C allele carriers, but solidly typical. Environmental factors (morning light, meal timing, consistent schedule) are the primary levers for shaping rhythm.

For carriers of one or two C alleles, the RGS16 mechanism shifts the clock toward earlier timing. The practical benefit — alignment with conventional work schedules and better morning alertness — is real but modest at this single locus. The main risk is the rigid early clock: evening social or professional demands can conflict acutely with a biologically advanced sleep phase, and C allele carriers typically find it harder to stay up late without next-day consequences.

Interactions

rs12736689 and rs516134 both tag the same RGS16 regulatory region (r² ~0.89 with rs1144566). Carriers with other morningness variants — in CLOCK (rs1801260), PER3 (rs5751876), PER2 (rs55694368), or the VIP signaling gene (rs9479402) — may experience additive phase advances. Evening-allele carriers at multiple circadian loci show the greatest benefit from structured morning-light and meal-timing interventions to advance their clock.

Dystrophin¹¹ Dystrophin
A 427 kDa cytoskeletal protein encoded by one of the largest genes in the human genome, spanning 2.4 Mb on the X chromosome. It forms a critical mechanical link between the intracellular actin cytoskeleton and the extracellular matrix in both skeletal and cardiac muscle. is the protein that keeps muscle fibres from tearing apart during every contraction. When full-length dystrophin is lost, the sarcolemma becomes fragile, membrane micro-ruptures accumulate with each heartbeat, and cardiomyocytes die faster than they can be replaced — culminating in dilated cardiomyopathy (DCM)²² dilated cardiomyopathy (DCM)
A form of heart failure in which the ventricles enlarge and weaken, reducing the heart's pumping capacity. In DMD-associated DCM, this is the direct result of dystrophin-deficient cardiomyocyte death..

The rs128627256 variant — NM_004006.3:c.8713C>T (p.Arg2905Ter) in the full-length muscle isoform Dp427m — converts an arginine codon to a premature stop codon in the last exon region of the dystrophin rod domain. It is classified as pathogenic in ClinVar (Variation 11288) and is associated with Duchenne muscular dystrophy, Becker muscular dystrophy, and dilated cardiomyopathy 3B (OMIM 302045) depending on the degree of residual protein produced and the specific isoforms affected.

The Mechanism

Full-length dystrophin (Dp427) is expressed in both skeletal and cardiac muscle. Shorter isoforms (Dp260, Dp140, Dp71) are expressed in the retina, brain, and other tissues. The p.Arg2905Ter nonsense mutation introduces a premature stop codon that triggers nonsense-mediated mRNA decay³³ nonsense-mediated mRNA decay
A cellular quality-control pathway that degrades mRNAs containing premature stop codons, preventing production of truncated proteins that could be toxic. for the full-length isoforms, eliminating or severely reducing full-length dystrophin protein. Without dystrophin, the dystrophin-associated protein complex (DAPC) at the sarcolemma disassembles, leaving the muscle cell membrane unanchored and vulnerable to contraction-induced damage.

In the heart, this loss is insidious: cardiac cells do not regenerate the way skeletal muscle does, so each injury event is permanent. Over years to decades, cumulative cardiomyocyte loss leads to ventricular dilation, fibrosis, and progressive systolic dysfunction. Cardiomyopathy occurs in nearly all males with DMD after age 18, and heart failure from DCM is the most common cause of death in Becker muscular dystrophy⁴⁴ heart failure from DCM is the most common cause of death in Becker muscular dystrophy
In BMD, skeletal muscle involvement is milder and patients survive longer, making the cardiac phenotype the dominant clinical problem. Mean age of death from cardiac causes is in the mid-40s..

The Evidence

GeneReviews Dystrophinopathies⁵⁵ GeneReviews Dystrophinopathies
Darras et al., updated 2022 — PMID 20301298 synthesises decades of natural history data: cardiomyopathy affects approximately one-third of DMD males by age 14, one-half by age 18, and virtually all by adulthood. Complete cardiac evaluation is recommended at least every two years from diagnosis, with annual evaluations from approximately age 10.

For female carriers, the picture is more nuanced. A systematic review by Ishizaki et al. (2018) — PMID 29801751⁶⁶ Ishizaki et al. (2018) — PMID 29801751 found dilated cardiomyopathy in 7.3–16.7% of female DMD carriers, with frequency increasing with age. A focused review by Lim et al. (2020) — PMID 32650403⁷⁷ Lim et al. (2020) — PMID 32650403 placed the overall DCM rate at ~8% of female carriers, while noting heterogeneity driven by X-inactivation patterns: females with skewed X-inactivation (where the variant-bearing X is preferentially active) face substantially higher cardiac risk than those with balanced inactivation.

An analysis of adult-onset DCM cohorts by Johnson et al. (2023) — PMID 37671549⁸⁸ Johnson et al. (2023) — PMID 37671549 found pathogenic DMD variants in 12.5% of unselected male DCM probands, with high rates of heart failure, transplantation, and ventricular arrhythmias — underscoring that DMD-associated DCM is not rare in adult cardiology practice, even when the neuromuscular diagnosis was never made.

Practical Actions

The cardiac risk from DMD variants is manageable with systematic early surveillance. In males with a confirmed DMD pathogenic variant, Bourke et al. (2022) — PMID 36252992⁹⁹ Bourke et al. (2022) — PMID 36252992 recommend cardiac MRI in addition to echocardiography, with ACE inhibitors or angiotensin receptor blockers initiated when left ventricular ejection fraction (LVEF) falls below 55% (or sometimes prophylactically), and beta-blockers added when LVEF falls below 45%. Heart transplant and mechanical circulatory support are options for end-stage disease.

For female carriers, GeneReviews recommends¹⁰¹⁰ GeneReviews recommends a complete cardiac evaluation by a specialist in late adolescence or early adulthood, then every five years from age 25–30. Any new cardiorespiratory symptoms warrant earlier evaluation. Pregnancy increases cardiac demands and is a recognized trigger for decompensation in carrier females — obstetric teams should be aware of carrier status.

Genetic counseling is essential for the extended family. In X-linked inheritance, an affected male passes the variant to all daughters (who become obligate carriers) and no sons. A carrier female has a 50% chance of passing the variant to each son (who would be affected) and each daughter (who would become a carrier).

Interactions

No inter-SNP compound action is warranted for this variant. Cardiac risk in males depends primarily on the presence of any pathogenic DMD variant that abolishes full-length dystrophin, rather than on interactions with other common SNPs. In females, cardiac risk is modulated by X-inactivation status¹¹¹¹ X-inactivation status
The process by which one X chromosome is silenced in each cell of a female. If the variant-bearing X is disproportionately active (skewed X-inactivation), more cells produce defective dystrophin and cardiac risk rises substantially. but this is not captured by a second SNP — it requires X-inactivation assays. DMD gene variants that truncate different isoforms may show variable skeletal muscle severity, but cardiac involvement is broadly present across truncating variants.